Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2011

01-09-2011 | Case Report

Spontaneous Remission in Localized Diffuse Large B-cell Lymphoma

Authors: László Tamás, Eszter Sári, Gábor Répássy, Péter Szabó, Enikő Bagdi, László Krenács, Judit Demeter

Published in: Pathology & Oncology Research | Issue 3/2011

Login to get access

Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive neoplastic disease of the lymphatic system, the activated B-cell type of this disease is likely to have a substantially worse prognosis. In this study, we report the favorable outcome of the activated B-cell type of DLBCL, though untreated, 7 years after diagnosis. In 2003, DLBCL localized to the root of tongue was found in the patient complaining of dysphonia and a pharyngeal globus perception but the patient did not agree to get any active hematological treatment. During the following years, the patient did not have any complaints. At the otorhinolaryngological control examination, in 2010, she was complaint-free, had normal laboratory parameters. Moreover a PET-CT scan did not reveal metabolic activity relating to malignancy. The extraordinary disease process can be explained by the spontaneous regression of the activated B-cell type DLBCL. Spontaneous regression of oral lymphoma has been published only exceptionally. To our knowledge, no report of spontaneous regression of activated B-cell type DLBLC has been reported.
Literature
1.
Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511PubMedCrossRef
2.
Chang CC, McClintock S, Ronald P et al (2004) Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol 28:464–470PubMedCrossRef
3.
Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282PubMedCrossRef
4.
Papac RJ (1999) Spontaneous regression of cancer. Cancer Treatment Reviews 22:395–423CrossRef
5.
Sengupta N, MacFie TS, MacDonald TT et al (2010) Cancer immunoediting and “spontaneous” tumor regression. Path Res and Pract 206:1–8CrossRef
6.
Fujimoto K, Endo T, Nishio M et al (2009) Complete remission of splenic marginal zone lymphoma after an acute flare-up of hepatitis B in a hepatitis B virus carrier. Int J Hematol 90:601–604PubMedCrossRef
7.
Drobyski WR, Qazi (1989) Spontaneous regression in non-Hodgkin’s lymphoma: clinical and pathogenic considerations. Am J Hem 31:138–141CrossRef
8.
Gattiker HH, Wiltshaw E, Galton DAG (1980) Spontaneous regression in non-Hodgkin ’s lymphoma. Cancer 45:2627–2632PubMedCrossRef
9.
Krikorian JG, Carol S, Cooney DP et al (1980) Spontaneous regression of non-Hodgkin’s Lymphoma: a report of nine cases. Cancer 46:2093–2099PubMedCrossRef
10.
Abe R, Ogawa K, Maruyama Y et al (2007) Spontaneous regression of diffuse large B-cell lymphoma harbouring epstein-barr virus: a case report and review of the literature. J Clin Exp Hematopathol 47:23–26CrossRef
11.
Evans LS, Hancock B (2003) Non-Hodgkin lymphoma. The Lancet Vol 362:139–146CrossRef
12.
Daly RM, Healy CM, Toner ME et al (2008) Spontaneous regression of non-Hodgkin’s lymphoma int he oral cavity after incisional biopsy. Br J Or Maxillofac Surg 46:223–225CrossRef
13.
Savarrio L, Gibosn J, Dunlop DJ et al (1999) Spontaneous regression of an anaplastic large cell lymphoma int he oral cavity: first reported case and review of the literature. Or Onc 35:609–613CrossRef
14.
Koga M, Kusukawa J, Havabuchi N (2003) Spontaneous regression of extranodal malignant lymphoma occurred int he gingiva. Or Onc 39:323–324CrossRef
15.
Iqbal J, Greiner TC, Patel K et al (2009) Gene expression profiling in lymphoma diagnosis and management. Best Pract & Res Clin Haem 22:191–210CrossRef
16.
Camilleri-Broet S, Criniére E, Broet P et al (2006) A uniform activated B-cell-like immunophenotpye might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood 107:190–196PubMedCrossRef
17.
Lu X, Nechushtan H, Ding F et al (2005) Distinct IL-4-induced gene expression, proliferation, and intracellular signaling in germinal center B-cell like and activated B-cell –like diffuse large-cell lymphomas. Blood 105(7):2924–2932PubMedCrossRef
18.
Barrans SL, Carter I, Owen RG et al (2002) Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 99:1136–1143PubMedCrossRef
19.
20.
21.
Liu Y-H, Xu FP, Zhuang HG et al (2008) Clinicopathologic significance of immunphenotypic profiles related to germinal center and activation B-cell differentiation in diffuse large B-cell lymphoma from Chinese patients. Hum Path 39:875–884PubMedCrossRef
22.
Pfreundschuh M (2010) How I treat elderly patients with diffuse large B-cell lymphoma. Blood 116:5103–10PubMedCrossRef
23.
Miller TP, Unger JM, Spier CM et al (2004) Effect of adding rituximab to three cycles of CHOP plus involved –field radiotherapy for limited –stage agressive diffuse B-cell lymphoma ( SWOG-0014). Blood 104:48a
24.
Persky DO, Unger JM, Spier CM et al (2008) Phase II study of rituximab plus three cycles of CHOP and involved –field radiotherapy for patients with limited-stage agressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 26(14):2258–2263PubMedCrossRef
Metadata
Title
Spontaneous Remission in Localized Diffuse Large B-cell Lymphoma
Authors
László Tamás
Eszter Sári
Gábor Répássy
Péter Szabó
Enikő Bagdi
László Krenács
Judit Demeter
Publication date
01-09-2011
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2011
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-011-9379-6

Other articles of this Issue 3/2011

Pathology & Oncology Research 3/2011 Go to the issue

Research

Study of the Differentially Expressed Genes in Pleomorphic Adenoma Using cDNA Microarrays

Research

Glucocorticoid Receptor Expression and Antiproliferative Effect of Dexamethasone on Human Melanoma Cells

Research

Relationship Between Hypermethylated MGMT Gene and Osteosarcoma Necrosis Rate After Chemotherapy

Research

Distribution, Incidence, and Prognosis in Neuroendocrine Tumors: a Population Based Study from a Cancer Registry

Research

The Evaluation of CD99 Immunoreactivity and EWS/FLI1 Translocation by Fluorescence in situ Hybridization in Central PNETs and Ewing’s Sarcoma Family of Tumors

Research

Embryonic Vasculogenesis in Nodular Melanomas and Tumour Differentiation
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits